Phase 2 Readouts — Q3 2026
Phase 2 trials test drug efficacy in 100-300 patients with the target condition. Positive Phase 2 data validates the drug mechanism and sets the stage for pivotal Phase 3 trials.
20 phase 2 readouts in Q3 2026. Updated .
Phase 2 Readout: laromestrocel
Longeveron Inc. (LGVN)
Phase 2 Readout: elpis ii
Longeveron Inc. (LGVN)
Phase 2 Readout: rademikibart
Connect Biopharma Holdings Ltd (CNTB)
Phase 2 Readout: evorpacept
ALX ONCOLOGY HOLDINGS INC (ALXO)
Phase 2 Readout: intranasal foralumab
Tiziana Life Sciences Ltd (TLSA)
Phase 2 Readout: nxc-201
Immix Biopharma, Inc. (IMMX)
Phase 2 Readout: sl-325
Shattuck Labs, Inc. (STTK)
Phase 2 Readout: ml-007c-ma
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: pipeline candidate
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: nimacimab
Skye Bioscience, Inc. (SKYE)
Phase 2 Readout: nexicart-2
JOHNSON & JOHNSON (JNJ)
Phase 2 Readout: divesiran
Silence Therapeutics Plc (SLN)
Phase 2 Readout: ep-104gi
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Phase 2 Readout: gt-02287
Gain Therapeutics, Inc. (GANX)
Phase 2 Readout: namodenoson
Can-Fite BioPharma Ltd. (CANF)
Phase 2 Readout: piclidenoson
Can-Fite BioPharma Ltd. (CANF)
Phase 2 Readout: bezisterim
BIOVIE INC. (BIVI)
Phase 2 Readout: pali-2108
PALISADE BIO, INC. (PALI)
Phase 2 Readout: RA
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: revita
Fractyl Health Inc. (GUTS)